Levothyroxine BE [Design Issues]

posted by pjs – India, 2015-07-29 13:32 (3519 d 03:16 ago) – Posting: # 15166
Views: 6,959

Dear all,

We are preparing three strengths of the Levothyroxin sodium oral solution 25 mcg/5ml, 50 mcg/5ml and 100 mcg/5ml for EMA submission.

Any one could provide some reference for the pharmacokinetic linearity of the same.

Also is levothyroxine considered as a NTI?

RMS is UK.

Thanks.
Regards,
PJS

Complete thread:

UA Flag
Activity
 Admin contact
23,409 posts in 4,921 threads, 1,666 registered users;
26 visitors (0 registered, 26 guests [including 12 identified bots]).
Forum time: 15:48 CET (Europe/Vienna)

There are only two kinds of scholars;
those who love ideas and those who hate them.    Emile Chartier

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5